These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34547589)

  • 21. Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia.
    Okada H; Tada H; Hayashi K; Kawashima H; Takata T; Sakata K; Nohara A; Mabuchi H; Yamagishi M; Kawashiri MA
    J Atheroscler Thromb; 2018 Jul; 25(7):634-642. PubMed ID: 29321389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular disease onset in old people with severe hypercholesterolemia.
    Coutinho ER; Miname MH; Rocha VZ; Bittencourt MS; Jannes CE; Krieger JE; Pereira AC; Santos RD
    Atherosclerosis; 2023 Jan; 365():9-14. PubMed ID: 36646017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
    Silva PR; Jannes CE; Marsiglia JD; Krieger JE; Santos RD; Pereira AC
    Atherosclerosis; 2016 Jul; 250():144-50. PubMed ID: 27214396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
    Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.
    Duell PB; Santos RD; Kirwan BA; Witztum JL; Tsimikas S; Kastelein JJP
    J Clin Lipidol; 2016; 10(4):1011-1021. PubMed ID: 27578134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
    D'Erasmo L; Minicocci I; Di Costanzo A; Pigna G; Commodari D; Ceci F; Montali A; Brancato F; Stanca I; Nicolucci A; Ascione A; Galea N; Carbone I; Francone M; Maranghi M; Arca M
    J Am Heart Assoc; 2021 May; 10(9):e018932. PubMed ID: 33890476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
    Hu P; Dharmayat KI; Stevens CAT; Sharabiani MTA; Jones RS; Watts GF; Genest J; Ray KK; Vallejo-Vaz AJ
    Circulation; 2020 Jun; 141(22):1742-1759. PubMed ID: 32468833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Svendsen K; Krogh HW; Igland J; Tell GS; Mundal LJ; Holven KB; Bogsrud MP; Leren TP; Retterstøl K
    Atherosclerosis; 2021 Feb; 319():28-34. PubMed ID: 33465659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia.
    Ellis KL; Pérez de Isla L; Alonso R; Fuentes F; Watts GF; Mata P
    J Am Coll Cardiol; 2019 Mar; 73(9):1029-1039. PubMed ID: 30846097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation.
    Petrov I; Postadzhiyan A; Vasilev D; Kasabov R; Tokmakova M; Nikolov F; Istatkov V; Zhao B; Mutafchiev D; Petkova R
    Adv Ther; 2021 May; 38(5):2323-2338. PubMed ID: 33754300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia.
    Agarwala A; Deych E; Jones LK; Sturm AC; Aspry K; Ahmad Z; Ballantyne CM; Goldberg AC
    J Clin Lipidol; 2023; 17(1):150-156. PubMed ID: 36470719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke: Copenhagen General Population Study.
    Beheshti S; Madsen CM; Varbo A; Benn M; Nordestgaard BG
    Circulation; 2018 Aug; 138(6):578-589. PubMed ID: 29593013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Familial hypercholesterolemia related admission for acute coronary syndrome in the United States: Incidence, predictors, and outcomes.
    Kheiri B; Simpson TF; Osman M; Balla S; Rahmouni H; Mehta A; Pokharel Y; Nasir K; Fazio S; Shapiro MD
    J Clin Lipidol; 2021; 15(3):460-465. PubMed ID: 34053910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia.
    Paquette M; Bernard S; Ruel I; Blank DW; Genest J; Baass A
    J Clin Lipidol; 2019; 13(1):123-128. PubMed ID: 30318454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia.
    Tada H; Okada H; Nohara A; Takamura M; Kawashiri MA
    Atherosclerosis; 2022 Jan; 340():28-34. PubMed ID: 34871818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study.
    Iyen B; Qureshi N; Kai J; Akyea RK; Leonardi-Bee J; Roderick P; Humphries SE; Weng S
    Atherosclerosis; 2019 Aug; 287():8-15. PubMed ID: 31181417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Circ J; 2017 Dec; 82(1):218-223. PubMed ID: 28701632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.